Docket: AR226-1781

All documents tagged with this AR226 identifier.

Page 1 of 2 — 174 documents
Title / Summary Year AR226 Docket Hash ID Pages
3M submitted a TSCA 8(e) supplemental report to the EPA indicating that an oral pharmacokinetic study in rats showed that perfluorooctanesulfonyl fluoride (POSF) metabolizes to perfluorooctane sulfonate (PFOS), with maximum PFOS levels in the liver observed at 11 ppm on day 4 post-dose. 2004 AR226-1781 GKRop6GvaONM9Z4LOV0wyJb0m 1
3M submitted a supplemental report to the EPA regarding a lactational and placental transport pharmacokinetic study in rats involving ammonium perfluorooctanoate (PFOA), following previous communications about related reproductive studies. 2004 AR226-1781 RwK63rQRNzkO876JjQxyzR78 1
This document is a correspondence from 3M to the EPA, providing additional background information and data regarding monitoring programs related to perfluorinated chemicals, specifically including a Carbon Adsorption Study for the removal of PFOA from wastewater. 2004 AR226-1781 ZBM9beEJL2EORG8edy0BJzjJY 2
The document details the sample tracking of wildlife samples from Michigan State University that were analyzed for concentrations of perfluorinated compounds at 3M, including sample IDs and storage conditions. 2004 AR226-1781 ymaqz7rq14BjD5XknNnkKwnD4 8
3M submitted additional data and revised reports on perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), and related compounds to the EPA, including corrections to ecotoxicological studies based on new analyses of sample purity. 2004 AR226-1781 O1Vo56Z6GLnyaeQKOexVXr7me 13
This document reports on a study evaluating the metabolism and toxicological effects of perfluorooctanesulfonamide (FOSA) in male rats, comparing its effects to other compounds, with a focus on hepatic peroxisome proliferation after administering a dose of 40 mg/kg/day for four consecutive days. 2004 AR226-1781 EdBQjM8EJ7qwY8vBD02O3egzj 19
3M submitted an electronic copy of its "Environmental and Health Assessment of Perfluorooctane Sulfonic Acid and its Salts" to the EPA, which integrates available data regarding PFOS. 2003 AR226-1781 k6EyBVg6DbrO8GezrrQkQz0EO 1
3M submitted information to the EPA regarding perfluorooctane sulfonates and related compounds, including a pharmacokinetic study of potassium perfluorooctanoate in cynomolgus monkeys, as part of their ongoing dialogue about fluorochemicals. 2003 AR226-1781 v6R9EkVDoENNjDnnZwRg9pbaE 1
3M submitted a series of assay validation and analysis reports to the EPA regarding the quantitative determination of perfluorooctane sulfonate (PFOS) and related compounds in human serum, as part of their ongoing dialogue about fluorochemicals. 2003 AR226-1781 1QOa7yGe6Drmkzodd164OOQKj 2
This is a letter from a medical director regarding a PFOA/PFOS-related inquiry, dated January 27, 2003, with no analytical content retained in the OCR. 2003 AR226-1781 wrGqwqR2NyBzgemQ5nkRXNRy6 1
3M submitted voluntary data on perfluorooctane sulfonates, including results from bacterial mutation and chromosome aberration tests, to the EPA as part of their ongoing dialogue regarding fluorochemicals. 2003 AR226-1781 v1eonYpbe2Ke54NV0r4ZdY418 1
This is a letterhead cover page from 3M, with no analytical content retained in the OCR. 2003 AR226-1781 o932DvEn2e64Jv7z211B528Lo 1
The report details a study conducted by 3M Company on serum concentrations of perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS) among 38 employees from the Cottage Grove plant, revealing that 11 participants had PFOA levels exceeding the Biologic Limit Value of 5 ppm, while PFOS levels were significantly lower, 2003 AR226-1781 ZJg0xZxeVyQ50wgpOwe6BxdXZ 13
The document is a final report from 3M Company assessing the relationship between serum levels of perfluorooctanoate (PFOA) and lipid, hepatic, and thyroid function among its production workforce, revealing a geometric mean serum PFOA concentration of 0.85 ppm among male employees. 2003 AR226-1781 mmq4oDjRZwKnoYMDwRYyYrBKZ 41
The report details a study conducted by 3M Company on serum concentrations of fluorochemicals, including PFOS and PFOA, among 54 employees from their Decatur, Alabama plant, finding that while PFOS levels remained stable, PFOA levels showed a decline, with none exceeding the biological limit value. 2003 AR226-1781 GmqYveJROK1RNzLZmkXO9g0V4 20
This document reports on a pharmacokinetic study of potassium perfluorooctanesulfonate (PFOS) conducted by Southern Research Institute for 3M Corporation, revealing that serum concentrations of PFOS in cynomolgus monkeys decreased rapidly within the first 24 hours post-administration but remained relatively constant until Day 70, after which they gradually declined. 2003 AR226-1781 JNm2aRjr3mxR8DbvmmDJ6qbev 58
This document reports on a pharmacokinetic study of potassium perfluorohexanesulfonate conducted by Southern Research Institute on cynomolgus monkeys, revealing significant serum concentration levels and urinary excretion patterns following administration. 2003 AR226-1781 oeYMeoLJ6O4o8EZb1dY5Gx0y8 57
This document is a final report on a pharmacokinetic study of potassium perfluorooctanoate (PFOA) conducted on cynomolgus monkeys by Southern Research Institute for 3M Corporation, which found that serum concentrations of PFOA declined over time, with notable differences between male and female monkeys in the rate of decrease. 2003 AR226-1781 pmzv2x7zEGVJrMOYdw0ZNZrjB 61
The document details a toxicity study on perfluorooctane sulfonate (PFOS) conducted by 3M, assessing its effects on various terrestrial plant species using artificial soil, with a purity of 86.9%, following EPA guidelines. 2003 AR226-1781 JrqjzZDBR5mMDbRxgXke6gz2B 12
The document is a final report from the University of Dayton Research Institute detailing laboratory-scale thermal degradation studies of Perfluoro-Octanyl Sulfonate (PFOS) and related substances, conducted under the direction of 3M Environmental Lab from March 2001 to December 2002. 2003 AR226-1781 e773wN1jQgz7Lr7kg4ZdX5M39 159
3M is submitting additional data on perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), and related compounds to the EPA as part of their ongoing dialogue, including organized studies and a redacted Protein Binding Study report. 2003 AR226-1781 2j6Z1R9B99rvabN9VoLvwRwag 9
The document reports on a fluorochemical medical surveillance program conducted in 2003 for 30 employees at 3M's Antwerp manufacturing site, revealing serum PFOA concentrations ranging from 0.92 to 5.69 ppm, with two participants exceeding the company's biological limit value of 5 ppm, while PFOS concentrations showed a decrease compared to previous years. 2003 AR226-1781 jdmBga96xGZqwZZQQmdvbxo2 16
The document is a Good Laboratory Practice-compliant study report from Exygen Research, sponsored by 3M Environmental Technology and Safety Services, detailing the extraction of potassium perfluorooctanesulfonate (PFOS) from red blood cells and serum for analysis using HPLC-Electrospray/Mass Spectrometry. 2003 AR226-1781 KJKo2bnLebRVyj3MYZjBm9RQQ 98
This document is a revised report by Mark E. Ellefson from the 3M Environmental Laboratory detailing the analysis of samples from the Tennessee River Valley, specifically focusing on perfluorinated compounds, as part of study #E02-0443. 2003 AR226-1781 qd8EKD405VVbKZy56z8DjVkZE 276
The document is a final report on a combined repeated dose toxicity study of the test substance T-7706, which includes assessments of reproductive and developmental toxicity in male and female rats. 2003 AR226-1781 ym96DEGdwaQ0pKd0MNMNnkJMV 769
This analytical report from Exygen Research details the characterization of water and sediment samples for perfluorinated compounds, specifically analyzing perfluorooctanoic acid (PFOA), perfluorooctanesulfonate (PFOS), and other fluorochemicals using liquid chromatography/tandem mass spectrometry (LC/MS/MS). 2003 AR226-1781 wgXVG5j5JwX5N45jKQD2BkVGo 465
3M submitted a final report on a toxicity study of perfluorooctanesulfonate (PFOS) to the EPA, confirming results consistent with previously reported information. 2003 AR226-1781 ga3Z378LLVZnR7LYdjYqEBK4V 1
3M submitted a final report to the EPA regarding an oral combined repeated dose toxicity study with reproductive/developmental toxicity screening test on perfluorohexane sulfonate potassium salt (PFHS), confirming results consistent with previously reported information. 2003 AR226-1781 0LgrpqGq017yL3Jz7nNRJm2ax 2
The document is a study report from 3M titled "Analysis of Endogenous Fluorochemicals in Normal Pooled Human Serum and Plasma," conducted under Good Laboratory Practice standards, focusing on the analysis of fluorochemicals, including PFOA and PFOS, in human serum and plasma. 2002 AR226-1781 JNzO3erZ8oKjRpY5wX8OQ60M2 226
3M submitted a series of analytical reports and a biodegradation study to the EPA regarding perfluorooctanoic acid (PFOA) and related compounds, including findings on isomer distribution and validated analytical methods for detecting PFOS in biological samples. 2002 AR226-1781 zQRN9dX8XY0gOOy4On7xe5B1g 4
This is a biodegradation study report (Revision 1) prepared by Pace Analytical Services for 3M, detailing the biodegradation screen study for telomer-type alcohols under Project Number E01-0684. 2002 AR226-1781 em24gY3z04zmxYXGvKprz1K79 38
3M submitted a supplemental notice to the EPA regarding draft reproduction studies on Perfluorooctanesulfonate (PFOS) conducted on northern bobwhite and mallard ducks, indicating that while some feed levels caused toxicity, the 10ppm group showed no significant reproductive effects compared to controls, although further analytical results are pending. 2002 AR226-1781 V3e4KyDXoL3zjv9QL0bg32wON 2
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding Ammonium Perfluorooctanoate (APFO), CAS# 3825-26-1, detailing statistically significant adverse effects observed in a reproduction study on rats, including decreased lactation index and delays in sexual maturation, while noting that further analysis is needed to understand the causation of these effects 2002 AR226-1781 B5eMkd12X1M81V3KgZz12xLxX 1
3M submitted a supplemental notice to the EPA regarding reproduction studies on Perfluorooctanesulfonate (PFOS) conducted on northern bobwhite and mallard ducks, indicating that while some feed levels caused toxicity, the 10 ppm group showed no significant reproductive effects compared to controls, although further analytical results are pending. 2002 AR226-1781 RayDJ1ndox1LdrG7rpDK72Z58 2
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding Ammonium Perfluorooctanoate (APFO), highlighting statistically significant adverse effects observed in a reproduction study on rats, including decreased lactation index and delayed sexual maturation, while noting that further analyses are needed to clarify causation. 2002 AR226-1781 qdpo5KwjOXn0b3MbKqL9VxbRn 1
The document is a report from 3M regarding a bacterial reverse mutation test for perfluorooctanesulfonyl fluoride (POSF), conducted by Huntingdon Life Sciences, issued on October 23, 2002. 2002 AR226-1781 8X47ydxaZLyE1vdxbe0QGwQy 29
The document is a report from 3M regarding a mammalian chromosome aberration test conducted on perfluorooctanesulfonyl fluoride (POSF) by Huntingdon Life Sciences, issued on October 22, 2002. 2002 AR226-1781 QgqMMv7JyBo8X4EVm1b20aBRL 28
The document is a final report of a 4-week toxicity study on Perfluorooctane Sulfonic Acid (PFOS) conducted by 3M in Cynomolgus monkeys, indicating compliance with EPA Good Laboratory Practice standards despite a noted GLP deviation during prestudy procedures. 2002 AR226-1781 2Jz0YkME7GdkZKz7gjNzrrqza 238
The document is a report from 3M regarding an in vitro mammalian chromosome aberration test conducted on perfluorooctanesulfonyl fluoride (POSF) using human lymphocytes, issued by Huntingdon Life Sciences Ltd on October 22, 2002. 2002 AR226-1781 e57n4MdN0JjnQBbw5Oo08Ld64 28
This document is a bacterial reverse mutation test report for perfluorooctanesulfonyl fluoride (POSF) conducted by Huntingdon Life Sciences Ltd. for 3M, issued on October 23, 2002, assessing the mutagenic potential of the substance. 2002 AR226-1781 QxQKp2k5q4d8opZNbdd9Rv2R 29
This document establishes a Lifetime Drinking Water Health Advisory of 4 pg/L for perfluorooctanesulfonate (PFOS), based on EPA methodology and assumptions regarding water consumption. 2002 AR226-1781 peebRk8RDwVKx7nkgGzZLQNQd 6
3M submitted a series of reports and studies to the EPA regarding perfluorooctane sulfonates (PFOS) and related compounds, including toxicity studies, health advisories, and analytical results, as part of their ongoing dialogue about fluorochemicals. 2002 AR226-1781 rxY88rOrD7gQwbMN8mLZZnGBE 2
The Toxikon final report on the CHO/HGPRT forward mutation assay indicates that Ammonium Perfluorooctanoate (PFOA) did not induce mutations at the HGPRT locus, as there was no significant increase in mutant colonies compared to negative controls. 2002 AR226-1781 zQ05kkzVNxbExQG4edVR7pjbB 29
The document reports on a study conducted by 3M to determine the presence and concentration of Perfluorooctane Sulfonate (PFOS) in serum and liver samples of Cynomolgus monkeys, following a 26-week toxicity study, and confirms compliance with EPA Good Laboratory Practice standards. 2002 AR226-1781 gbzX3mQrp0edBeGZOV6Gg8KoQ 113
This document presents a benchmark dose (BMD) assessment for liver tumors in Sprague Dawley rats fed Perfluorooctane Sulfonic Acid Potassium Salt (PFOS), detailing the methodology for calculating the BMDLio for hepatocellular adenomas and carcinomas based on chronic toxicity and carcinogenicity study data. 2002 AR226-1781 1QR7Yb4pEabq9Nz8y8wGOxDNm 4
The document discusses the calculation of benchmark doses (BMDL) for tumors in Sprague Dawley rats fed N-Ethyl Perfluorooctanesulfonamido Ethanol (N-EtFOSE), focusing on thyroid and liver tumors in male and female rats, respectively. 2002 AR226-1781 pmm7xzazer21E2J806J6ybr77 8
3M is submitting multiple reports to the EPA regarding perfluorooctane sulfonates (PFOS) and perfluorooctanoate (PFOA), including studies on their identification in human sera and analyses of their serum levels in relation to various health parameters. 2002 AR226-1781 Eq9jMMbnMN0Qrbnz1Y82wrE2b 2
The document is a final report on a one-generation reproduction study of PFOS conducted in rats, detailing methods, results, and conclusions regarding the effects of PFOS on reproduction and development. 2002 AR226-1781 2jr8wmYK03VQJ9K01EVYR1zgL 1087
The document summarizes various environmental studies conducted by 3M related to selected fluorochemicals, including PFOA, in the Decatur, Alabama area, detailing sampling events, analytical reports, and monitoring data from 2000 to 2004. 2002 AR226-1781 J3yroLwowqbGYZVYrvX0n0bBe 1
The document outlines various environmental studies conducted by 3M regarding selected fluorochemicals, including PFOA, in the Decatur, Alabama area, detailing sampling events, analytical reports, and monitoring data from 2000 to 2004. 2002 AR226-1781 34jX7r4Xq2gknbM55613bm3n 1
The document summarizes various environmental studies and health assessments related to Perfluorooctanesulfonate (PFOS) conducted by 3M between February 2002 and May 2004, including soil absorption/desorption studies, thermal degradation research, and ecotoxicity tests. 2002 AR226-1781 qavYoDX0D7DXgdXYBx2JkQ7ZE 5
The document summarizes various environmental studies and health assessments related to Perfluorooctanesulfonate (PFOS) conducted by 3M between February 2002 and May 2004, including soil absorption studies, thermal degradation research, and ecotoxicity tests. 2002 AR226-1781 0qd8yR9eOaGeLRyZRkk35yn2d 1
The document is a final report on a toxicokinetic study of perfluorooctanesulfonamide (FOSA) in rats, conducted by 3M and submitted on May 11, 2004. 2002 AR226-1781 qkvVE9X2xQXkwaJy39RbB419q 1
The document outlines various studies and reports submitted by 3M regarding the identification and analysis of fluorochemicals, specifically PFOS and PFOA, in human sera, including findings from medical surveillance programs and epidemiological studies conducted between February 2002 and May 2004. 2002 AR226-1781 Qg7gk1kobjxvk0Lwz3LZOLwOE 3
The document contains submissions from 3M regarding the toxicology and reproductive effects of N-Ethylperfluorooctanesulfonamidoethanol (N-EtFOSE), including benchmark doses for tumors in rats and a report amendment on a two-generation reproduction study. 2002 AR226-1781 rBwpx3pYQK1Lp8R7QkddNEpB7 1
The document outlines submissions by 3M regarding toxicology, epidemiology, and medical surveillance studies on perfluorohexane sulfonate (PFHS), including a pharmacokinetic study in cynomolgus monkeys and a repeated-dose toxicity study. 2002 AR226-1781 pewMkN88Yey1MgxrREOkxe1NE 1
The document summarizes various studies submitted by 3M between February 2002 and May 2004 regarding the toxicology, pharmacokinetics, and reproductive effects of perfluorooctanoic acid (PFOA) and its ammonium salt (APFO) in animal models, including a pharmacokinetic study in cynomolgus monkeys and a two-generation reproduction study in rats 2002 AR226-1781 n9qBxzgbmKVwEBExR1LgeORB2 2
The document summarizes various studies and reports submitted by 3M regarding the environmental and health assessment of Perfluorooctanesulfonate (PFOS), including toxicological, pharmacokinetic, and ecotoxicological evaluations conducted between February 2002 and May 2004. 2002 AR226-1781 QX4RGxBeb5jKNmzRp1L1Dyz0R 2
The document summarizes various toxicological studies conducted by 3M on Perfluorooctanesulfonyl fluoride (POSF), including acute inhalation toxicity, oral toxicity rangefinding in rats, genotoxicity tests, and pharmacokinetic studies, submitted between 2002 and 2004. 2002 AR226-1781 bJd2DK3LnxDwXxY501DXZyL1 1
This document appears to be a summary of 3M fluorochemical submissions related to various chemicals, including PFOS and PFOA, spanning from February 2002 to May 2004, with sections on toxicology, epidemiology, medical surveillance, and environmental studies. 2002 AR226-1781 p29Oywd3LYG60wYZ88zk8O83X 1
The document is an index of submissions by 3M to the AR-226 docket, specifically noting a preliminary study from October 30, 2002, regarding the oral toxicity and reproductive/developmental effects of Perfluorohexane Sulfonate Potassium Salt (PFHS). 2002 AR226-1781 LJXv2mY3E0xMxGMLX0j3e0z9w 1
The document provides an index of submissions by 3M related to ammonium perfluorooctanoate (APFO) from April 2002, including a final report on a two-generation reproduction study in rats and supplemental information under TSCA. 2002 AR226-1781 KJ5dxp93gmJd2LnoymnOD8yqQ 1
The document is an index of submissions by 3M related to fluorochemicals, including studies on biodegradation and analyses of fluorochemicals in human serum samples conducted between December 2002 and May 2004. 2002 AR226-1781 kDRQqLzDMDRMjLd2VdmERoQND 1
The document is an index of 3M's submissions related to PFOS and ammonium perfluorooctanoate (APFO) under TSCA 8(e) from February 2002 to May 2004, including notices of draft reports on reproduction studies involving Northern Bobwhite and Mallard as well as a two-generation reproduction study in rats. 2002 AR226-1781 Ddy5Nd47waZa5Jm6N8ZYGx9EB 1
The document is an index of submissions by 3M related to perfluorinated compounds, specifically detailing various studies and reports on perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS) conducted between February 2002 and May 2004. 2002 AR226-1781 mpomx6kGEK2RagZjQeoxXYBGZ 1
The document is a submission cover letter from 3M, dated May 10, 2002, which includes an addendum to a two-generation reproduction study of ammonium perfluorooctanoate (PFOA) in rats, conducted by Argus Research and Charles River Laboratories. 2002 AR226-1781 OxOyG321DmJkk2YO48RJJwEM 1
The document provides an index of submissions by 3M related to fluorochemicals, including reports on the identification and analysis of PFOS and PFOA in human sera and their health implications from various studies conducted between February 2002 and May 2004. 2002 AR226-1781 xz7BYmxgMQpNyxLnQa4JRYGYb 1
The document presents raw estrous cycling data from a two-generation reproduction study of ammonium perfluorooctanoate (PFOA) in rats conducted by 3M, including analysis and graphical representations of the findings. 2002 AR226-1781 8VgzXkO7JXXo0rDw9NpYeVBoe 1
The document is an index of submissions by 3M related to the environmental and health assessment of Perfluorooctane Sulfonic Acid (PFOS) and its salts, including robust summaries of various studies conducted between August 2002 and May 2004. 2002 AR226-1781 RjOmZkk1LnD4x6XYNK1NKGjmV 1
The document is a submission cover letter for a pharmacokinetic study of potassium perfluorooctanoate (PFOA) conducted by Southern Research Institute, dated February 13, 2003. 2002 AR226-1781 nr3KoG55NXbLxjq97dzNRRzX 1
The document is an index of submissions by 3M related to perfluorinated compounds, specifically detailing various studies and reports on Perfluorooctanesulfonyl Fluoride (POSF) and Perfluorooctane Sulfonate (PFOS) conducted between January 2002 and May 2004, including bacterial mutation tests and serum analysis reports. 2002 AR226-1781 ypg2e87maprVaB9bd1dY02m12 1
The document provides an index of submissions by 3M related to fluorochemicals, specifically highlighting a final report on the oral toxicity study of T-7706 (PFHS) and another report on fluorochemical levels in rats, both submitted in September 2003. 2002 AR226-1781 oe9Or9RmO10OMJoYM7M4L4978 1
The document is an index of submissions by 3M related to perfluorinated compounds, specifically detailing various health hazard evaluations, toxicology studies, and serum concentration analyses for substances such as Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS) from July 2002 to May 2004. 2002 AR226-1781 71DpEGwKgmYNwo39K6vGZB2vj 2
The document is an index of submissions by 3M related to PFOA and other fluorochemicals from February 2002 to May 2004, including various studies and reports on biosphere monitoring, wastewater treatment, and environmental analysis in Decatur, AL. 2002 AR226-1781 GK00bwGLwjLbNmyZRopm1wjyY 1
The document is a submission cover letter from 3M dated February 24, 2004, accompanying a final report on a pharmacokinetic study of perfluorooctanesulfonyl fluoride (POSF) following a single oral gavage dose in rats. 2002 AR226-1781 93bBkLgaG5z31XXXnr13LMQKL 1
The document indexes submissions by 3M related to PFOA studies conducted by DuPont Haskell Laboratory between January 2002 and May 2004, including reports on lactational and placental transport pharmacokinetics and age effects on plasma concentration in post-weaning rats. 2002 AR226-1781 37kvKZ6n4Kp08v7kRr5GxvG8J 1
Empty document. 2002 AR226-1781 4aYkMg6qZVb279y2vNZ63OGbe 1
This is a document outlining the arrangement of 3M fluorochemical submissions from February 2002 to May 2004, categorized by chemical study type and date. 2002 AR226-1781 qm2yJD5pxb8wRNy73ze3B4x6k 1
The document is an index of submissions by 3M related to perfluorinated compounds, specifically detailing various reports and studies on PFOA and PFOS, including serum concentration analyses and toxicity investigations conducted between February 2002 and May 2004. 2002 AR226-1781 LBd9wQbZ9p9y4DZ2kYN2xed 5
The document outlines the ongoing RCRA interim remedial measures program by 3M at the Decatur site to construct a containment structure for an inactive landfill, including the installation of a subsurface sheet-piling barrier and an upgraded multilayer cap to prevent groundwater contamination from perfluorinated compounds. 2002 AR226-1781 85moxqxkxp3g4GajDa9Q5GDbd 1
This final report from 3M Company details the identification and quantitative analysis of fluorochemicals, including PFOS and PFOA, in serum samples from elderly participants in a cognitive function study in Seattle, revealing a geometric mean concentration of PFOS at 31.0 ppb. 2002 AR226-1781 rx6D14XqvXVZ2pZML5D9nGM2J 31
The document is a final report from 3M Company detailing a study that identified and quantified the presence of seven fluorochemicals, including perfluorooctanesulfonate (PFOS), in serum samples from pediatric participants in a clinical trial, with a reported geometric mean concentration of PFOS at 37.5 ppb. 2002 AR226-1781 ZBv8MgR3LnwXqgp7RmZj0Dpbd 48
The document is a final report from 3M Company detailing a study that analyzed 645 serum samples from American Red Cross adult blood donors for seven fluorochemicals, including perfluorooctanesulfonate (PFOS), with a reported geometric mean concentration of PFOS at 34.9 ppb. 2002 AR226-1781 a1ExGNMZ53Qape6v1gzQ4B369 39
This interim report from 3M Company details an ongoing study to determine the serum half-lives of PFOS and PFOA in humans, revealing that PFOS may have a half-life of 139-640 days and PFOA approximately one year, while addressing concerns about the accuracy of previous measurements. 2002 AR226-1781 341gpZgQYgj67v7xJwJV5o4E 22
3M submitted a TSCA Section 8(e) Supplemental Notice to the EPA, providing final reports related to the identification and analysis of fluorochemicals, including PFOS and PFOA, in human sera and their relation to clinical health metrics. 2002 AR226-1781 0R1bGzzevqDR0p5dNyeBqEwx 2
3M submitted a TSCA Section 8(e) Supplemental Notice to the EPA, providing final reports on the identification and analysis of fluorochemicals, including PFOA and PFOS, in human sera and their relation to clinical health metrics. 2002 AR226-1781 bawmq6n7gqw2rYq02e4dkDm7Z 2
This document reviews the genotoxicity, carcinogenicity, and reproductive effects of perfluorooctanoate (PFOA) based on animal and human studies, concluding that PFOA does not present an unreasonable risk to human health at current exposure levels, despite laboratory findings indicating potential health hazards. 2002 AR226-1781 VJDDKB61YKQ4qM2YZNx6o9bZZ 23
This document is a revised report prepared for 3M by Entrix, Inc. detailing the survey of selected fluorochemicals, including PFOA and PFOS, in the Decatur, Alabama area based on sampling conducted in 2002. 2002 AR226-1781 LgX3kL7rqydKkrkpJaDgyV1NQ 42
3M submitted a report on a two-generation reproduction study of Ammonium Perfluorooctanoate (APFO) in rats to the EPA as part of their ongoing dialogue regarding perfluorooctane sulfonates and related compounds. 2002 AR226-1781 LJ8nmyGEoN2zVJ1GLYV3Ea145 2
The document is a submission from 3M to the EPA regarding a final report on a two-generation reproduction study in rats involving Ammonium Perfluorooctanoate (CAS# 3825-26-1), as part of a TSCA 8(e) notice. 2002 AR226-1781 Re15NJEEyxBxvy7yLbG3Bowa 1
The document is an Analytical Phase Report for a reproduction study on PFOS conducted by 3M Environmental Laboratory, which outlines compliance with TSCA GLP standards and includes quality assurance statements regarding the study's methodology and data handling. 2002 AR226-1781 jZZeB6B7zo3mEq4Q4BJexrvO 216
The document is an analytical phase report for a reproduction study on PFOS conducted with the Northern Bobwhite by 3M Environmental Laboratory, detailing compliance with TSCA GLP standards and noting certain exceptions. 2002 AR226-1781 red6bkmpmLKG2Kn54eLd4oavV 226
3M submitted additional data to the EPA regarding a two-generation reproduction study on ammonium perfluorooctanoate, focusing on the effects of gestational age and body weight on reproductive outcomes in rats. 2002 AR226-1781 RaEkmxzZrBv7V1LDpVLJ9VJoE 1
3M submitted a TSCA Section 8(e) substantial risk notice to the EPA regarding findings from a toxicity study on perfluorohexane sulfonate potassium salt (PFHS), indicating adverse effects in parental male rats, including increased liver weight and thyroid cell changes, while no effects were observed in parental females. 2002 AR226-1781 reQorbXEw330jpO4aDnJ6YG8J 2
3M submitted raw estrous cycling data and analyses related to ammonium perfluorooctanoate (PFOA) to the EPA as part of their ongoing dialogue regarding fluorochemicals, following a meeting on August 30, 2002, where toxicology studies were discussed. 2002 AR226-1781 da26RoE9nO0kNw1KvdXVb6eRR 3
The document is a correspondence from Jo Ann Frazee at Argus Research to Dr. John Butenhoff at 3M, providing estrous cycle evaluation data for a two-generation reproduction study of Ammonium Perfluorooctanoate (APFO) in rats. 2002 AR226-1781 g2NKV7Nkzvodz77DB72qr345Q 43
This document presents estrous cycling and litter observation data for rats exposed to varying doses of ammonium perfluorooctanoate (APFO), detailing cycle lengths, incidence of aberrant cycles, and reproductive outcomes such as implantations, liveborn, and stillborn counts across different dose groups. 2002 AR226-1781 nkvB7Be4ymnvE9je3OXZxR3ow 2
The document reports on an acute inhalation toxicity study of perfluoroctanesulfonyl fluoride (POSF) conducted by 3M, which found that rats exposed to 1000 ppm of POSF for 4 hours showed no significant adverse effects and had measurable levels of perfluorooctane sulfonate (PFOS) in urine and serum. 2001 AR226-1781 O3n5RM9zqLQZpDJOOgoJzy651 18
This document details the analytical method validation for the determination of perfluorooctanesulfonate (PFOS) in artificial soil, conducted by Wildlife International, Ltd. for 3M Corporation, and completed in compliance with Good Laboratory Practice Standards. 2001 AR226-1781 RJyjMZ6y8vg04e7V9eVwD0xbX 46
This final report details a toxicity test conducted by Wildlife International, Ltd. for 3M Corporation to assess the effects of PFOS on the seedling emergence of seven plant species, completed in compliance with Good Laboratory Practice Standards. 2001 AR226-1781 jgKKNKr6zKKd86yjnDwEm4Nxk 136